Kulu State Hospital, Department of Medical Biochemistry, Kulu, Konya, Turkey.
Bilecik Seyh Edebali University, Faculty of Science and Letters, Department of Molecular Biology and Genetics, Bilecik, Turkey.
Microrna. 2020;9(4):303-309. doi: 10.2174/2211536609666201106090458.
Prostate Cancer (PCa) is the second most common cancer in males and the fifth in cancer-associated mortality. Although the Prostate-Specific Antigen (PSA) test is widely used in PCa screenings, it has significant limitations in the differential diagnosis of PCa. Therefore, studies on developing new biomarkers for PCa diagnosis are ongoing. MiRNAs are good candidate biomarkers for the diagnosis of cancers, including prostate cancer, as they can be easily detected from circulation.
In this study, it is aimed to determine the diagnostic value of serum levels of miR-223-3p and -223-5p in Benign Prostate Hyperplasia (BPH), Chronic Prostatitis (CP) and Prostate Cancer (PCa).
Serum samples were collected from 68 patients in total (25 BPH, 10 CP, 33 PCa). MiR-223- 3p and -223-5p levels were measured in serum with qRT-PCR. The Ct values of miRNAs were normalized according to the Ct value of ce-miR-39 and calculated -ΔCt values were used for statistical analyses.
The serum levels of miR-223-3p and -223-5p were downregulated in the PCa and CP groups, compared to the BPH group. There was no statistically significant difference between PCa and CP groups. The sensitivity and specificity of miR-223-3p, -223-5p and their combination were calculated as 88% and 88%; 86% and 79%; 93% and 92% in discriminating BPH and PCa groups, respectively.
In this study, it was shown that miR-223-3p and -223-5p were both detectable in circulation. miR-223-3p, -223-5p, and their combination may be good candidate biomarkers for prostate cancer diagnosis. Also, observation of similar serum levels of miR-223-3p and -223-5p between CP and PCa groups suggests that miR-223 may play a role in prostate cancer development originated from chronic inflammation.
前列腺癌（PCa）是男性中第二常见的癌症，也是癌症相关死亡率的第五大原因。尽管前列腺特异性抗原（PSA）测试广泛用于 PCa 筛查，但它在 PCa 的鉴别诊断中存在显著局限性。因此，目前正在研究开发用于 PCa 诊断的新生物标志物。miRNAs 是癌症（包括前列腺癌）诊断的良好候选生物标志物，因为它们可以从循环中轻松检测到。
本研究旨在确定血清 miR-223-3p 和 -223-5p 水平在良性前列腺增生（BPH）、慢性前列腺炎（CP）和前列腺癌（PCa）中的诊断价值。
共采集 68 例患者的血清样本（25 例 BPH、10 例 CP、33 例 PCa）。采用 qRT-PCR 检测血清中 miR-223-3p 和 -223-5p 水平。根据 ce-miR-39 的 Ct 值对 miRNA 的 Ct 值进行归一化，并计算 -ΔCt 值进行统计分析。
与 BPH 组相比，PCa 和 CP 组血清 miR-223-3p 和 -223-5p 水平下调。PCa 和 CP 组之间无统计学差异。miR-223-3p、-223-5p 及其组合区分 BPH 和 PCa 组的灵敏度和特异性分别为 88%和 88%；86%和 79%；93%和 92%。
本研究表明，miR-223-3p 和 -223-5p 均可在循环中检测到。miR-223-3p、-223-5p 及其组合可能是前列腺癌诊断的良好候选生物标志物。此外，CP 和 PCa 组之间血清 miR-223-3p 和 -223-5p 水平相似，提示 miR-223 可能在起源于慢性炎症的前列腺癌发展中发挥作用。
